Santen Pharmaceutical Co., Ltd. (TYO:4536)
Japan
· Delayed Price · Currency is JPY | Market Cap | 540.09B |
| Revenue (ttm) | 287.99B |
| Net Income (ttm) | 30.60B |
| Shares Out | 321.67M |
| EPS (ttm) | 91.84 |
| PE Ratio | 18.28 |
| Forward PE | 14.84 |
| Dividend | 38.00 (2.21%) |
| Ex-Dividend Date | Mar 30, 2026 |
| Volume | 558,800 |
| Average Volume | 991,810 |
| Open | 1,639.00 |
| Previous Close | 1,679.00 |
| Day's Range | 1,622.00 - 1,658.50 |
| 52-Week Range | 1,310.50 - 1,790.50 |
| Beta | 0.34 |
| RSI | 41.21 |
| Earnings Date | Feb 5, 2026 |
About Santen Pharmaceutical
Santen Pharmaceutical Co., Ltd. engages in the research and development, manufacturing, and marketing of pharmaceuticals and medical devices in Japan, China, Asia, Europe, the Middle East, Africa, and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2α derivative and a beta-adrenergic receptor blocker for the treatment of glaucoma and ocular hypertension; ciclosporin, an ophthalmic emulsion for the treatment of vernal keratoconjunctivitis, as well as latanoprost, an ophthalmic emulsion of a prostaglan... [Read more]
Financial Performance
In fiscal year 2025, Santen Pharmaceutical's revenue was 300.00 billion, a decrease of -0.65% compared to the previous year's 301.97 billion. Earnings were 36.25 billion, an increase of 36.09%.
Financial StatementsNews
Santen Pharmaceutical Co., Ltd. GAAP EPS of ¥66.05, revenue of ¥210.76B
Santen Pharmaceutical Co., Ltd. (SNPHY) Management on Q1 2022 Results - Earnings Call Transcript
Santen Pharmaceutical Co., Ltd. (OTCPK:SNPHY) Q1 2022 Earnings Conference Call August 4, 2022 3:30 AM ET Company Participants Peter Sallstig - Chief Medical Officer Conference Call Participants Peter ...